• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    The Valens Company Obtains Final Court Order Approving The Proposed Plan Of Arrangement With SNDL; Under The Terms Of The Arrangement, Valens' Shareholders Will Receive, For Each Common Share Of Valens, 0.3334 Of A Common Share Of SNDL

    1/3/23 1:22:01 PM ET
    $SNDL
    $VLNS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SNDL alert in real time by email

     The Valens Company Inc. (TSX:VLNS) (NASDAQ:VLNS) ("The Valens Company" or "Valens"), a leading manufacturer of cannabis products, is pleased to announce today that the Ontario Superior Court of Justice (Commercial List) has granted a final order approving the previously announced plan of arrangement (the "Arrangement") with SNDL Inc. ("SNDL") under Section 192 of the Canada Business Corporations Act in accordance with the terms of the arrangement agreement between Valens and SNDL dated August 22, 2022.

    Under the terms of the Arrangement, Valens' shareholders will receive, for each common share of Valens (each, a "Valens Share"), 0.3334 of a common share of SNDL (the "Offer Exchange Ratio"). Based on the closing price of the SNDL shares on the Nasdaq Capital Market (the "Nasdaq") as at August 19, 2022, the consideration represents an implied value of $1.26 per Valens Share (the "Implied Offer Price"), for total consideration of approximately $138 million.

    Completion of the Arrangement remains subject to certain other customary closing conditions as further described in the Arrangement Agreement, and, subject to the satisfaction or waiver of such closing conditions, the Arrangement is expected to be completed during January 2023.

    The Arrangement Agreement, including further information on the conditions precedent to completion of the Arrangement, is described in the management information circular and proxy statement of Valens dated October 24, 2022, which has been filed on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar and is available on Valens' website at www.thevalenscompany.com.

    Get the next $SNDL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNDL
    $VLNS

    CompanyDatePrice TargetRatingAnalyst
    SNDL Inc.
    $SNDL
    9/3/2025$5.00Buy
    Alliance Global Partners
    SNDL Inc.
    $SNDL
    7/17/2024Speculative Buy
    Canaccord Genuity
    SNDL Inc.
    $SNDL
    8/16/2022$5.00Hold → Speculative Buy
    Canaccord Genuity
    SNDL Inc.
    $SNDL
    5/3/2022$0.60 → $0.70Underperform → Market Perform
    BMO Capital Markets
    The Valens Company Inc.
    $VLNS
    3/3/2022Market Perform → Underperform
    Raymond James
    More analyst ratings

    $SNDL
    $VLNS
    SEC Filings

    View All

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    3/30/26 5:35:45 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    3/12/26 6:55:05 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    2/19/26 4:40:03 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SNDL Announces Leadership Transition for Cannabis Segment

    EDMONTON, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") announced today that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL's current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours. ABOUT SNDL INC. SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquo

    3/30/26 5:00:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

    EDMONTON, Alberta, March 12, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the full year and fourth quarter ended December 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, March 12, 2026. The conference call details can be found below. MANAGEMENT HIGHLIGHTS Net revenue for the fourth quarter of 2025 was $252.

    3/12/26 6:55:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL to Report Fourth Quarter 2025 and Full Year 2025 Financial Results on March 12, 2026

    EDMONTON, Alberta, Feb. 19, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before markets open on Thursday, March 12, 2026. Following the release of its fourth quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on March 12, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/aps8jm4e ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integr

    2/19/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on SNDL Inc. with a new price target

    Alliance Global Partners initiated coverage of SNDL Inc. with a rating of Buy and set a new price target of $5.00

    9/3/25 7:54:28 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Canaccord Genuity resumed coverage on SNDL Inc.

    Canaccord Genuity resumed coverage of SNDL Inc. with a rating of Speculative Buy

    7/17/24 12:19:57 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Sundial Growers upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Sundial Growers from Hold to Speculative Buy and set a new price target of $5.00

    8/16/22 7:59:34 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    Financials

    Live finance-specific insights

    View All

    SNDL Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

    EDMONTON, Alberta, March 12, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the full year and fourth quarter ended December 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, March 12, 2026. The conference call details can be found below. MANAGEMENT HIGHLIGHTS Net revenue for the fourth quarter of 2025 was $252.

    3/12/26 6:55:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL to Report Fourth Quarter 2025 and Full Year 2025 Financial Results on March 12, 2026

    EDMONTON, Alberta, Feb. 19, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before markets open on Thursday, March 12, 2026. Following the release of its fourth quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on March 12, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/aps8jm4e ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integr

    2/19/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL & 1CM Complete Purchase and Sale of 5 Retail Stores in Alberta and Saskatchewan

    EDMONTON, Alberta and TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") and 1CM Inc. (CSE:EPIC) (OTCQB:MILFF) (FSE: IQ70) ("1CM") are pleased to announce that SNDL has completed the acquisition of 5 cannabis retail stores located in Alberta and Saskatchewan from 1CM. The transaction represents the completion of the first closing pursuant to the amended and restated arrangement agreement dated December 15, 2025 (the "A&R Arrangement Agreement"). As previously announced, it is anticipated that the second (and final) closing will occur sometime in the first half of 2026, in respect of 27 additional cannabis retail stores located in Ontario, subject to obta

    1/7/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    1/31/24 4:48:48 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Subject)

    2/14/23 5:28:02 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    2/13/23 4:06:09 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    Leadership Updates

    Live Leadership Updates

    View All

    SNDL Announces Leadership Transition for Cannabis Segment

    EDMONTON, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") announced today that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL's current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours. ABOUT SNDL INC. SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquo

    3/30/26 5:00:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Announces 2025 Annual and Special Meeting Results

    EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual and Special Meeting of Shareholders (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at seven (7); (ii) electing each of Gregory Mills, J. Carlo Cannell, Lori Ell, Zachary George, Frank Krasovec, Bryan Pinney, and Gregory Turnbull as directors of the Company for the ensuing year; (iii) re-appointing CBIZ

    7/31/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Appoints New Chief Information Officer and New President, Liquor Division

    CALGARY, AB, Nov. 21, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the appointments of Phil McBride as Chief Information Officer and Navroop Sandhawalia as President, Liquor Division. "SNDL's success is driven by our commitment to talent density and our leaders are the foundation of our performance culture," said Zach George, Chief Executive Officer of SNDL.  "Phil's extensive expertise in technology and digital innovation, paired with Nav's financial acumen and best-in-class retail experience will further strengthen our executio

    11/21/24 6:02:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care